X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Neurotherapeutics

期刊標題檢索 NEUROTHERAPEUTI 最新評論: Instant rejection, only accepting top 10% original research, review i... (2023-11-10)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Neurotherapeutics]您好,您是該頁面的第 41206 位訪客。

期刊簡介
期刊名稱Neurotherapeutics Neurotherapeutics
LetPub Score
7.8
50 ratings
Rate

Reputation
8.7

Influence
6.6

Speed
9.6

期刊簡稱NEUROTHERAPEUTICS
ISSN1933-7213
E-ISSN1878-7479
h-index100
CiteScore
CiteScoreSJRSNIPCiteScore Rank
11.001.6251.418
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q114 / 272
Category: Medicine
Subcategory: Neurology (clinical)
Q132 / 400
Category: Medicine
Subcategory: Pharmacology
Q130 / 313

自引率 (2023-2024)1.80%自引率趨勢
掲載範囲
Neurotherapeutics® is the journal of the American Society for Experimental Neurotherapeutics (ASENT). Each issue provides critical reviews of an important topic relating to the treatment of neurological disorders written by international authorities.

The Journal also publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field.

Neurotherapeutics ® delivers a multidisciplinary perspective on the frontiers of translational neuroscience, provides perspectives on current research and practice, and covers social and ethical as well as scientific issues.
官方網站https://www.springer.com/13311
在線稿件提交https://www.editorialmanager.com/nerx/
開放訪問No
出版商Springer International Publishing
主題領域医学
出版國/地區UNITED STATES
發行頻率四半期刊行
創刊年2004
每年文章數108每年文章數趨勢
黃金OA百分比98.33%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
CLINICAL NEUROLOGYSCIEQ128/277
NEUROSCIENCESSCIEQ141/310
PHARMACOLOGY & PHARMACYSCIEQ131/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1933-7213%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Neurotherapeutics】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    NATURE REVIEWS NEUROSCIENCEH-index: 357

    CiteScore: 35.00
    NATURE NEUROSCIENCEH-index: 375

    CiteScore: 38.60
    Molecular NeurodegenerationH-index: 66

    CiteScore: 23.00
    NeuronH-index: 430

    CiteScore: 24.50
    TRENDS IN NEUROSCIENCESH-index: 269

    CiteScore: 26.50
    Annual Review of NeuroscienceH-index: 224

    CiteScore: 25.30
    Journal of NeuroinflammationH-index: 92

    CiteScore: 15.90
    PROGRESS IN NEUROBIOLOGYH-index: 212

    CiteScore: 12.80
    GLIAH-index: 148

    CiteScore: 13.10
    NEUROPSYCHOLOGY REVIEWH-index: 80

    CiteScore: 11.00
    學科內最受檢索的期刊 頁面查看次數
    Journal of Neuroinflammation196860
    NEUROSCIENCE189938
    JOURNAL OF NEUROSCIENCE185805
    BRAIN RESEARCH140176
    MOLECULAR NEUROBIOLOGY129332
    Neuron121663
    NEUROSCIENCE LETTERS115229
    CNS Neuroscience & Therapeutics110054
    NATURE NEUROSCIENCE98385
    CEREBRAL CORTEX98065
  •  

    Neurotherapeutics Neurotherapeutics
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Neurotherapeutics] 的評論撰寫評論
作者: kkkad


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2023-11-10 13:33:20 評論於
Instant rejection, only accepting top 10% original research, review invitation
(0) 讚! | kkkad

作者: 乌龙癸巳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-26 09:46:07 評論於
Do we need to submit original data for WB, etc.?
(0) 讚! | 乌龙癸巳

作者: 宫古夏真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-29 18:13:03 評論於
It's been a week and it's still stuck at Submitted to journal. Why is it so slow?
(0) 讚! | 宫古夏真

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 21:11:03 評論於
Sufficient experimental data results and well-written articles
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 09:19:45 評論於
Articles with a score of 7 or above will be accepted for publication upon submission of additional data and results
(0) 讚! | 维尔娜菲茨杰拉德

作者: 北国博达


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 19:47:28 評論於
What preparation do you need for camping in nature?
(0) 讚! | 北国博达

作者: 修然小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 14:20:41 評論於
Why do I think my article is only worth 3-4 points, but my supervisor wants to start rating it from 7 points or more?
(0) 讚! | 修然小公主

作者: 先天彭勃


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-04-03 14:39:15 評論於
Please translate the following paragraph into English and Japanese, and title them ":" and ":"
(0) 讚! | 先天彭勃

作者: 珉林琼岚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-07-22 18:25:04 評論於
Review Speed: 12.0 | Acceptance Rate: 25.0
Experience Sharing: A good journal with high requirements for images, but the review process is fast
(0) 讚! | 珉林琼岚

作者: 葵花天彤


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-02-05 13:45:02 評論於
Review Speed: 1.0
Experience Sharing: The review process is fast, the replies are also very friendly. After two major revisions, the article was published within one year, and no publication fee was charged! Thumbs up
(0) 讚! | 葵花天彤

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-16 20:10:23 評論於
Passing the 5-point threshold is a reason to rejoice. Climbing even higher next year by surpassing the 6-point threshold will be truly exceptional
(0) 讚! | 凌霄高洁

作者: 平原冷梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-06-15 16:58:15 評論於
Review Speed: 1.0
Experience Sharing: Submitted on May 10, external review on May 14, editor's rejection reply on June 15. Cannot resubmit but can receive some feedback and meet some satisfaction
(0) 讚! | 平原冷梅

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-06-29 18:06:05 評論於
Bullish, will it rise again next year?
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Neurotherapeutics] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*